Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody

作者：Guo Yongjing; Hill Andrew A; Ramsey Renee C; Immermann Frederick W; Corcoran Christopher; Young Deborah; LaVallie Edward R; Ryan Mark; Bechard Theresa; Pfeifer Richard; Warner Garvin; Bologna Marcia; Bloom Laird; O'Toole Margot^*

来源：Journal of Translational Medicine, 2010, 8: 50.

DOI：10.1186/1479-5876-8-50

Background: Selective neutralization of the IL21/IL21R signaling pathway is a promising approach for the treatment of a variety of autoimmune diseases. Ab-01 is a human neutralizing anti-IL21R antibody. In order to ensure that the activities of Ab-01 are restricted to neutralization even under in vitro cross-linking and in vivo conditions, a comprehensive assessment of agonistic potential of Ab-01 was undertaken.
Methods: In vitro antibody cross-linking and cell culture protocols reported for studies with a human agonistic antibody, TGN1412, were followed for Ab-01. rhIL21, the agonist ligand of the targeted receptor, and cross-linked anti-CD28 were used as positive controls for signal transduction. In vivo agonistic potential of Ab-01 was assessed by measuring expression levels of cytokine storm-associated and IL21 pathway genes in blood of cynomolgus monkeys before and after IV administration of Ab-01.
Results: Using a comprehensive set of assays that detected multiple activation signals in the presence of the positive control agonists, in vitro Ab-01-dependent activation was not detected in either PBMCs or the rhIL21-responsive cell line Daudi. Furthermore, no difference in gene expression levels was detected in blood before and after in vivo Ab-01 dosing of cynomolgus monkeys.
Conclusions: Despite efforts to intentionally force an agonistic signal from Ab-01, none could be detected.

• 出版日期2010-5-26